Sai Life Sciences Q2 FY27 Revenue Up 23% YoY to ₹659 Cr, EBITDA at ₹187 Cr
Sai Life Sciences reported Q2 FY27 revenue of ₹659 crore, a 23% YoY increase. EBITDA stood at ₹28 crore. For H1 FY27, revenue reached ₹1,213 crore (17% YoY growth) with EBITDA at ₹335 crore. The company invested ₹621 crore in capex in H1 FY27 and expects a stronger second half.
The strong financial performance, significant capex, and positive business updates are material to investors and indicate strong operational momentum and future growth prospects for the company.
The company reported strong year-on-year revenue growth of 23% for the quarter and 17% for the half-year, along with healthy EBITDA margins and significant capex investment indicating future growth. Management commentary also reflects optimism.
Sai Life Sciences Limited has announced its unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2026. The company reported a strong performance with revenue growing by 23% year-on-year to ₹659 crore for the second quarter (Q2 FY27). The EBITDA for the quarter stood at ₹187 crore, with EBITDA margins at 28%.
For the half-year ended September 30, 2026 (H1 FY27), the company's revenue was ₹1,213 crore, a 17% year-on-year increase. The EBITDA for H1 FY27 was ₹335 crore, with margins at 28%.
The company has invested ₹621 crore in capital expenditure (Capex) during the first half of FY27, with ₹358 crore invested in the second quarter. This investment is on track for the overall projection of ₹1,100 to ₹1,300 crore.
Krishna Kanumuri, MD & CEO, highlighted the strong quarter with continued business momentum and progress across strategic priorities, noting growing traction with global pharmaceutical companies and increasing adoption of their integrated outsourcing model. Siva Chittor, Whole-time Director & CFO, mentioned that the performance was broad-based with healthy growth in both CRO and CDMO segments, and expressed expectation for a stronger second half.
Business updates include the commencement of operations for their first end-to-end integrated collaboration, conversion of another large pharma relationship into a strategic engagement, and ongoing discussions to expand the integrated outsourcing model. The company also advanced one molecule to the late phase pipeline and another from late phase to commercial.
Sai Life Sciences' Units 2 and 4 received Zero Waste to Landfill Platinum certification. The company was also certified as a Great Place To Work® for 2026–27.
The Investor Presentation on these results was scheduled to be used during the Earnings Conference Call held on Friday, November 06, 2026, at 11:00 A.M. (IST).
What to do with a filing like this
Sai Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sai Life Sciences Limited. Read the original for the full detail.